Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Immunotherapy Opdivo (Nivolumab) Non-Squamous NSCLC Trial Stopped, Reported as Positive
Author
Howard (Jack) West, MD

In January, 2015, the CheckMate 017 trial of the immune checkpoint inhibitor Opdivo (nivolumab) versus the standard chemo agent Taxotere (docetaxel) as second line therapy for patients with advanced squamous NSCLC was reported in a press release to be positive for a significant improvement in overall survival. No further details were offered at that time, but additional data were submitted to the FDA just days before the FDA approved Opdivo on March 4, 2015 and made it commercially available for these patients (with the FDA deserving credit for seemingly waiting in a conference room to go through an immediate approval process once the full data was supplied). We have since learned that Opdivo was associated with a significant, 3.2 month improvement in median overall survival, 9.2 vs. 6.0 months, but additional data await presentation at the annual ASCO meeting in Chicago in late May/early June.

Bristol-Myers-Squibb  (BMS) ran a parallel trial called CheckMate 057, also directly comparing Opdivo to docetaxel as second line therapy for patients with non-squamous NSCLC, which comprises about 75-80% of NSCLC patients in North America.  That trial completed enrollment around the same time as the squamous trial, but no results were forthcoming until this week, when a press release from BMS noted that an interim data review from this trial has demonstrated a significant survival benefit again for Opdivo -- with no additional data offered yet. 

What does this mean for lung cancer patients? Lung cancer specialists have been following the trials for years and had been very optimistic that both trials would emerge as positive for a survival benefit with Opdivo, but after the FDA approval of this agent for the minority of patients with squamous NSCLC, we could only be hopeful that we'd see the same pattern of a favorable press release, rapid FDA approval once submission of the relevant data to the FDA was completed, and then prompt availability of the agent to the much broader advanced NSCLC patient community...but at some undetermined point in the future.

We now have a starting point for the next timeline, which could lead us to an approval for in non-squamous NSCLC  by the time of the ASCO meeting, if not before. In the meantime, I hope to find that my requests for insurer coverage for Opdivo for my patients with chemotherapy-pretreated advanced non-squamous NSCLC may be granted more easily. I've spoken with colleagues who have had some success getting coverage for Opdivo for their non-squamous NSCLC patients, but with the FDA approval for Opdivo pretty much imminent, I'd like to find that insurers don't bother to pursue policies that are histology-specific, since that policy will have a short half-life.

In the meantime, it's great to be able to look forward to another therapy. As new immunotherapy agents and combinations try to find their way into the marketplace, there will now be a higher bar to clear, which is great for lung cancer patients.

Next Previous link

Previous PostNext Post

Related Content

Image
Terapias Dirigidas de Cancer de Pulmón 2024
Video
La Dra. Estelamari Rodríguez presenta información básica sobre el NSCLC EGFR+ y analiza la importancia de las pruebas de biomarcadores en el cáncer de pulmón y ofrece una descripción general de las opciones de tratamiento para la enfermedad EGFR+.  Para ver la playlist completa, de click aquí.        
Image
2024-25 patient perspectives header
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!
Image
HPV Advances
Video
In this video series, Dr. Paul Romesser discusses recent advances in HPV related cancers, including treatment options, vaccination recommendations and patient perspectives.   To watch the full playlist click here.  

Forum Discussions

Hi Bluebird,  Welcome to GRACE.  I'm sorry you're going through this scare and hope it's just inflammation from an infection you didn't know you had. 

 

A CT would be the...

Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...

Hi and welcome to GRACE.  I'm sorry to know you are entering a new stage.  I'm not about to comment just now but wanted to let you know I see your...

Edit to say, we can't give advice but we can comment with views and facts.  :)

 

My first thought is to ask if she has been seen at a large...

Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...

Thank you, Janine, for answering so rapidly. I am aware that my nodules are small, but they scare me all the same. Your words that nodule measurements may vary somewhat when...

Hi Barbro,  I'm sorry you're worrying about this, and don't feel like you can discuss this with your doctor.  Speak to your doctor about this.  Let them know your worries and...

Recent Comments

JOIN THE CONVERSATION
Hi Bluebird,  Welcome to…
By JanineT GRACE … on
Hi Barbro,  I'm sorry you're…
By JanineT GRACE … on
General Lung/Thoracic Cancer
By Barbro Kristin… on
My first thought is to ask…
By JanineT GRACE … on